It wasn’t enough that they raised the price of this critical drug from $10 to $1,500 per dose. Now they are going after pharmacists and hitting pregnant low-income women the hardest.
KV Pharmaceutical Company is trying a new approach to corner the market for their drug Makena, which helps prevent premature births. They are “raising concerns” about the quality of 17P (17-Hydroxyprogesterone), a hormone that forms the active ingredient in the drug that has been used for many years by compounding pharmacies to make a low-cost version of the pregnancy medicine. The FDA has now agreed to investigate.